Nasdaq - Delayed Quote USD

Janus Henderson Global Life Sciences N (JFNNX)

70.99 +0.12 (+0.17%)
At close: 8:00 PM EDT

Performance Overview

Morningstar Return Rating --
YTD Return 2.73%
5y Average Return 11.28%
Number of Years Up 4
Number of Years Down 1
Best 1Y Total Return (Apr 25, 2024) 29.39%
Worst 1Y Total Return (Apr 25, 2024) --
Best 3Y Total Return 29.39%
Worst 3Y Total Return 3.90%

Trailing Returns (%) Vs. Benchmarks

Monthly Total Returns
JFNNX
Category
YTD
8.60%
7.95%
1-Month
1.74%
4.81%
3-Month
8.60%
7.18%
1-Year
18.38%
30.16%
3-Year
7.75%
16.10%
5-Year
11.71%
15.71%
10-Year
11.74%
15.27%
Last Bull Market
25.55%
23.06%
Last Bear Market
-8.23%
-13.88%

Annual Total Return (%) History

Year
JFNNX
Category
2024
--
--
2023
7.64%
--
2022
-2.57%
--
2021
6.94%
--
2020
25.74%
27.63%
2019
29.39%
26.23%
2018
--
-0.40%

Past Quarterly Returns

YearQ1Q2Q3Q4
2024 8.60% -- -- --
2023 -1.25% 4.71% -4.08% 8.53%
2022 -5.20% -8.23% -1.85% 14.10%
2021 -2.64% 7.12% -0.82% 3.39%
2020 -13.62% 21.10% 5.31% 14.13%
2019 13.90% 2.23% -6.53% 18.88%
2018 5.24% 10.14% -13.17% --

Rank in Category (By Total Return)

YTD 28
1-Month 54
3-Month 28
1-Year 18
3-Year 12
5-Year 8

Load Adjusted Returns

1-Year 18.38%
3-Year 7.75%
5-Year 11.71%
10-Year 11.74%

Performance & Risk

YTD Return 2.73%
5y Average Return 11.28%
Rank in Category (ytd) 28
% Rank in Category (ytd) --
Beta (5Y Monthly) 0.73
Morningstar Risk Rating

Fund Overview

Category Health
Fund Family Janus Henderson
Net Assets 5.37B
YTD Return 8.60%
Yield 0.20%
Morningstar Rating
Inception Date Jul 06, 2009

Fund Summary

The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio management believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

Related Tickers